![](https://news.europawire.eu/wp-content/uploads/2020/09/Sanofi-GSK-COVID19-vaccine-144x144.jpg)
Agreement signed today supports scale-up of manufacturing capabilities in several European countries Vaccine candidate uses Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system (PRESS RELEASE) PARIS, 18-Sep-2020 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused … Read the full press release